GlassScriptPhysician profile
Charles E Okpara
NPI 1174187744
$3,670.03
in general payments reported to CMS, 2019-2025
24 companies · $899 in 2025
The $899 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $542 · 2023: $1,097 · 2024: $970 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.65 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $726.06 | 2023-2025 | Monjuvi, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $369.89 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Seagen INC. | $277.98 | 2023 | Padcev, Tukysa |
| Janssen Biotech, INC. | $266.08 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Eisai INC. | $240.26 | 2022 | |
| Pfizer INC. | $185.47 | 2024-2025 | |
| Amgen INC. | $179.21 | 2021-2024 | |
| Gilead Sciences, INC. | $167.22 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $145.29 | 2022-2025 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $141.22 | 2023-2024 | Livtencity, Ninlaro |
| Karyopharm Therapeutics INC. | $130.69 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $126.95 | 2024 | Onureg |
| Kite Pharma, INC. | $116.36 | 2023 | |
| Genentech USA, INC. | $105.99 | 2021-2023 | Tecentriq |
| Regeneron Healthcare Solutions, INC. | $97.47 | 2022-2025 | Libtayo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $83.10 | 2021-2024 | |
| Celgene Corporation | $81.06 | 2023-2024 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $77.17 | 2024 | |
| Syndax Pharmaceuticals, INC. | $33.15 | 2025 | |
| Deciphera Pharmaceuticals INC. | $31.49 | 2023 | Qinlock |
| Sobi, INC | $29.50 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.23 | 2025 | |
| Exelixis INC. | $20.11 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $18.08 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Okpara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.